EMA Recommends Approval of 10 Drugs
The agency recommended approval of 11 drugs, including three cancer drugs, in September.
Updated 9/21/16
The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) recommended approval of 10 drugs during their Sept. 12–15, 2016 meeting. The approved drugs treat a range of conditions including different forms of cancer, type 2 diabetes, secondary hyperparathyroidism, heart failure, and HIV.
CHMP recommended the following:
- Conditional marketing authorization was given to Lartruvo, for the treatment of adults with advanced soft tissue sarcoma.
- Marketing authorization for Ibrance, for the treatment of locally advanced or metastatic breast cancer.
- Conditional marketing authorization for Ninlaro (ixazomib) for the treatment of multiple myeloma.
- Approval of Glyxambi (empagliflozin/linagliptin) for the treatment of type 2 diabetes.
- Approval of Parsabiv (etelcalcetide) for the treatment of secondary hyperparathyroidism.
- Positive opinion for Chenodeoxycholic acid sigma-tau (chenodeoxycholic acid) for the treatment of cerebrotendinous xanthomatosis.
CHMP also recommended the approval of four generic drugs: Ivabradine JensenR (ivabradine) and Ivabradine Zentiva (ivabradine) to treat angina pectoris and heart failure, Emtricitabine/ Tenofovir disoproxil Zentiva (emtricitabine/tenofovir disoproxil) to treat HIV infection, and Granpidam (sildenafil) for the treatment of patients with pulmonary arterial hypertension.
Source: EMA
FDA Approves First Treatment for Rare Lipid Storage Disease Cerebrotendinous Xanthomatosis
February 24th 2025Cerebrotendinous xanthomatosis, or CTX, is a metabolic disorder caused by a gene mutation that results in a deficiency of an important enzyme in the ability of the human body to break down fats.
FDA Grants Full Approval for Symptomatic Tenosynovial Giant Cell Tumor Treatment
February 18th 2025Tenosynovial giant cell tumor (TGCT) is rare and non-malignant, forming in or near joints, but which if left untreated can cause damage to joints and surrounding tissue, potentially leading to significant disability.
